Hot key words:
Recruits IM19 drug
Technological platform of CAR-T cell preparation

Chimeric antigen receptor (CAR) molecules are composed of an extracellular antigen-binding domain, a hinge domain, a transmembrane domain and intracellular signal domains. The extracellular antibody region specifically recognizes the surface antigens of tumor cells, activates intracellular signals, and induces T cells to kill tumor cells. Chimeric antigen receptor T cells (CAR-T) integrate the specificity of recognition of antibodies and the killing effects and memory functions of T cells. Immunochina has established an advanced technological platform of clinical-grade CAR-T cell preparation, developed a number of candidate CAR-T cellular products, and continuously optimized this technological platform to develop the next generation of CAR-T cellular products.


Technological platform of lentiviral vectors

Immunochina has established an advanced clinical-grade, large-scale technological platform of lentiviral vectors, which addresses the issues regarding safety and delivery of early lentiviral vectors. These lentiviral vectors can stably infect dividing and non-dividing cells and have greater carrying capacity. Based on this platform, a clinical-grade lentiviral vector for the preparation of CAR-T cellular products was successfully developed.


You are welcome to call for consultation! 010-62886890 Address:3rd Floor, B1 District, Yiyuan, 80 Xingshikou Road, Haidian District, Beijing
Beijing Immunochina Pharmaceuticals Co., Ltd. Copyright 京ICP备15031757号-1 Technical support: fast help cloud